R3HCC1L

Across TCGA pan-cancer cohorts, R3HCC1L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated R3HCC1L data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher R3HCC1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated R3HCC1L expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where R3HCC1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.215	0.745	<.001	30	view →
UCEC	DFS	Median	III,IV	1.000	0.531	.017	24	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
SKCM	DFS	Median	III,IV	1.000	0.597	.018	5	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

R3HCC1L–LUSC (OS)

Open the LUSC breakdown →